Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Prediction of Recurrence in Advanced Gastric Cancer After Radical Resection by Circulating Tumor Cells （CTCs）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01848015
• Other study ID #: CGOG5003
• Status: Recruiting
• Phase: N/A
• First received: May 3, 2013
• Last updated: May 17, 2015
• Start date: June 2013
• Est. completion date: June 2016

Study information

• Verified date: May 2015
• Source: Peking University
• Contact: Lin Shen, MD,PhD
• Phone: (86)10-88196175
• Email: lin100[@]medmail.com.cn
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

To assess the predictive value of circulating tumor cells (CTCs) for recurrence of advanced gastric cancer after radical resection.

To identify the relationship between the detection of circulation tumor cells and recurrence patterns of gastric cancer after radical resection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Having signed informed consent

• Age= 18 years old

• Histologically confirmed gastric adenocarcinoma

• Preoperative clinical examination and imaging indicating operable disease

• complete resection (R0 resection)

• D2 or D2+ resection

Exclusion Criteria:

• Other tumor type than adenocarcinoma

• Patients who have been given preoperative chemotherapy/chemoradiation.

• Staging investigations or intraoperative exploration indicating inoperable disease

• R1 or R2 resection

• D0 or D1 resection

• Patients unreliable for follow up

• Past history of malignancy

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Gastric Cancer
• Neoplastic Cells, Circulating
• Stomach Neoplasms

Intervention

Other:
• detection of CTCs

Locations

Country	Name	City	State
China	Peking cancer hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CTCs		2 months	No
Secondary	Recurrence of gastric cancer after radical resection		2 years	No